1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional) is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). This MIRA program provides substantial, flexible support for early career researchers to establish and maintain a cohesive research program within the NIGMS mission.
It aims to increase funding stability, encourage scientific creativity, and reduce administrative burden.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Maximizing Investigators' Research Award (MIRA) (R35) | National Institute of General Medical Sciences MIRA provides support for research in an investigator's laboratory that falls within the mission of NIGMS . The goal of MIRA is to increase the efficiency of NIGMS funding by providing investigators with greater stability and flexibility, thereby enhancing scientific productivity and the chances for important breakthroughs.
The program will also help distribute funding more widely among the nation's highly talented and promising investigators. MIRA grants will generally be for 5 years, for both established investigators/ new investigators and early stage investigators . Early stage investigators should apply through PAR-27-032 .
MIRA for Established and New Investigators (EIs and NIs) New NOFO Published: PAR-26-121 See below for MIRA for Early-Stage Investigators (ESIs). PAR-26-121 – Applications accepted in 2026-2028 MIRA Eligibility Decision Tree For more information on MIRA for established investigators contact Ashley Barnes, Ph. D.
, and Baishali Maskeri, Ph. D. , at NIGMS_EINIMIRA@nigms.
nih. gov MIRA for Early Stage Investigators (ESIs) PAR-27-032 - Applications accepted through February 6, 2029 FAQs About PAR-27-032 Eligibility: NIH Definitions of Early Stage Investigators and Related Policies and Procedures PAR-27-032: Informational Webinar on the NIGMS MIRA for ESIs (R35) - Video PAR-27-032: Informational Webinar on the NIGMS MIRA for ESIs (R35) - Slides For more information on MIRA for ESIs contact Michelle R.
Bond, Ph. D. , and Dimitrios Vatakis, Ph.
D. , at NIGMS-ESIMIRA@nigms. nih.
gov . This page last updated on
According to the current listing, eligibility includes: Early Stage Investigators (ESIs) who can devote at least 51% of their total research effort to the award. Only single PD/PI applications are allowed. Confirm the full requirements in the official notice before applying.
The current listing shows up to $250,000 direct costs per year for up to 5 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional) is funded by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article